NCT02231307已完成3 期
A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Clinical Efficacy and Safety of SUBLIVAC FIX Birch Immunotherapy in Patients Suffering From Allergic Rhinitis/Rhinoconjunctivitis Caused by Birch Pollen.
HAL Allergy39 个研究点 分布在 5 个国家目标入组 406 人开始时间: 2014年9月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 406
- 试验地点
- 39
- 主要终点
- combined symptom medication score
研究概览
简要总结
The aim of this phase III study is to asses if SUBLIVAC FIX Birch is safe and effective in reducing birch allergy induced symptoms and birch allergy medication usage.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent
- •Age ≥ 18 and ≤65 years
- •Moderate-to-severe birch pollen induced allergic rhinitis/rhinoconjunctivitis based on ARIA classification for at least 2 consecutive years
- •FEV1 (forced expiratory volume at one second) > 70% (of predicted value) for patients with a history of asthma, FEV1 > 70% or PEF (peak expiratory flow) > 80% (of predicted value) for patients without a history of asthma
- •Positive SPT (skin prick test) for birch pollen (mean wheal diameter ≥ 3mm compared to negative control; negative control should be negative; histamine control should be positive (mean wheal diameter ≥ 3mm)) assessed during screening.
- •Serum specific anti-birch IgE (immunoglobulin E) concentration >0.7 U/ml
- •Patients should be willing and capable to complete an e-diary daily during the birch pollen season (≥ 60% compliance in completion between Visit 1 and 2).
- •A positive Nasal Provocation Test to birch pollen at Visit 2 (Lebel score ≥ 6) or a documented positive test within 1 year before start of treatment
排除标准
- •Patients sensitized and symptomatic to pets should not be included if they are regularly exposed to pets
- •Specific immunotherapy (SCIT or SLIT) with birch pollen or a cross-reacting allergen within the last 5 years
- •SPT positive (mean wheal diameter ≥ 3mm compared to negative control; negative control should be negative; histamine control should be positive (mean wheal diameter ≥ 3mm)) patients to allergen(s) other than birch pollen, in the absence of a negative provocation test for this allergen(s) (within 1 year), who are expected to have clinically relevant symptoms during the birch pollen season
- •Completed unsuccessful allergen-specific immunotherapy (SCIT or SLIT) within the last 5 years
- •(Ongoing) allergen-specific immunotherapy (SCIT or SLIT) with any allergen(s) during the study period
- •Vaccination one week before start of treatment and/or during the up-dosing phase
- •Treatment with experimental products within the last 3 months or biologicals (including anti-IgE or TNF (tumor necrosis factor) - α treatment) within the last 6 months or during the study
- •Uncontrolled asthma or other active respiratory diseases
- •Clinically significant chronic sinusitis, ocular infection or severe inflammation of the oral mucosa
- •Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs
- •Active malignancies or any malignant disease in the last 5 years
- •Acute or chronic disease that in the opinion of the investigator is an additional risk for the patients, including but not limited to the following: cardiovascular insufficiency, any severe or unstable lung diseases, endocrine disorders, clinically significant renal or hepatic diseases, or haematological disorders
- •Diseases with a contra-indication for the use of adrenaline (e.g. hyperthyroidism, glaucoma)
- •Use of systemic corticosteroids 4 weeks before the study
- •Treatment with systemic or local β-blockers
- •Known hypersensitivity to any of the excipients (Disodium phosphate dihydrate, Sodium dihydrogen phosphate dehydrate, aminocaproic acid, Peppermint oil, Caramel Colorant or Glycerol)
- •A positive urine pregnancy test, lactation or inadequate contraceptive methods (adequate methods: oral contraceptives, IUD (intrauterine device), condom use and having no sexual relationship with a man)
- •Alcohol-, drug or medication abuse
- •Lack of co-operation or compliance
- •Severe psychiatric, psychological, or neurological disorders
- •Any physical or mental condition that precludes administration or allergen-specific immunotherapy, compliance or participation in a clinical trial
- •Patients who are employees of the department, 1st grade relatives, or partners of the investigator
- •Patients who have planned holidays outside the country for more than 7 continuous days during the defined pollen season (1st of March till 31st of May)
研究组 & 干预措施
SUBLIVAC FIX Birch 0 AUN/ml
Placebo Comparator
干预措施: SUBLIVAC FIX Birch (Drug)
SUBLIVAC FIX Birch 40,000 AUN/ml
Experimental
干预措施: SUBLIVAC FIX Birch (Drug)
结局指标
主要结局
combined symptom medication score
时间窗: 3 months
次要结局
- symptom score(3 months)
- Quality of Life questionnaires(3 months)
- Serum specific immunoglobulin levels(up to 9 months)
- local and systemic reactions(up to 9 months)
- (serious) adverse events(up to 9 months)
- blood safety parameters(up to 9 months)
- urinalysis(up to 9 months)
- medication score(up to 3 months)
研究者
研究点 (39)
Loading locations...
相似试验
已完成
2 期
SUBLIVAC FIX Birch Dose Tolerability/Dose Range FindingAllergic RhinitisAllergic RhinoconjunctivitisNCT01639768HAL Allergy270
已完成
2 期
SUBLIVAC FIX Phleum Pratense DT/DRFAllergic RhinoconjunctivitisAllergic RhinitisNCT01682070HAL Allergy266
已完成
3 期
Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1 Esterase Inhibitor for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary AngioedemaHereditary Angioedema (HAE)NCT02584959Shire75
已完成
3 期
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)Graft Versus Host DiseaseNCT00366145Mesoblast, Inc.260
已完成
2 期
SUBLIVAC® Birch PROBE StudySeasonal Rhinitis and/or RhinoconjunctivitisBirch Pollen AllergyNCT00932607HAL Allergy74